As­traZeneca's di­a­betes drug Farx­i­ga cuts risk of CV death or wors­en­ing of heart fail­ure by 26% in land­mark study

About two weeks af­ter As­traZeneca’s $AZN un­veiled its di­a­betes treat­ment Farx­i­ga cut the risk of CV death or the wors­en­ing of heart fail­ure in pa­tients with heart dis­ease, in a land­mark tri­al — over the week­end the British drug­mak­er pre­sent­ed de­tailed da­ta at the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy (ESC) Con­gress in Paris.

The re­sults em­anat­ed from the 4,744-pa­tient DA­PA-HF tri­al, which test­ed Farx­i­ga in pa­tients with re­duced ejec­tion frac­tion (HFrEF) — in which the heart mus­cle is not able to con­tract am­ply and, there­fore, ex­pels less oxy­gen-rich blood in­to the body — on stan­dard of care treat­ment, in­clud­ing those with and with­out type-II di­a­betes.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.